Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms

Phase 2

Terminated

• Conditions: Vasomotor Symptoms; Hot Flashes
• Interventions: Drug: RAD1901; Other: Placebo

• Registration Number: NCT02653417
• Lead Sponsor: Radius Pharmaceuticals, Inc.

Brief Summary

The primary objective of this study was to determine the clinical safety of RAD1901 and to evaluate whether RAD1901 reduced the frequency and severity of moderate to severe vasomotor symptoms (VMS; "hot flashes") in postmenopausal women.

Detailed Description

This was a Phase 2b outpatient, prospective, multicenter, double-blind, randomized, placebo-controlled study to determine whether elacestrant reduces the frequency and severity of vasomotor symptoms (VMS; "hot flashes") in postmenopausal women with moderate to severe hot flashes. Postmenopausal women who met study criteria were followed for 12 weeks on double-blind study medication and two weeks off study medication.

Treatment was randomized 1:1:1:1 to ensure that an approximately equal number of patients were exposed to each of three RAD1901 (elacestrant) doses (5, 10 and 20 mg/day) or placebo. The total period of placebo exposure was 14 weeks.

Enrolling approximately 300 patients was expected to provide power for testing superiority of the primary efficacy endpoint outcomes.

Study Timeline

• Study Start: 2015-12
• Study First Submitted: 2016-01-08
• Study First Submitted QC: 2016-01-11
• Study First Posted: 2016-01-12
• Primary Completion: 2016-12-12
• Study Completion: 2018-05-01
• Results First Submitted: 2018-10-15
• Status Verified: 2019-03
• Results First Submitted QC: 2019-03-12
• Last Update Submitted: 2019-03-12
• Results First Posted: 2019-03-13
• Last Update Posted: 2019-03-13

Recruitment & Eligibility

• Status: TERMINATED
• Sex: Female
• Target Recruitment: 139

Inclusion Criteria

To have participated in this study, a subject MUST:

1. be a postmenopausal woman between 40 and 65 years of age, inclusive
2. be seeking relief or treatment for moderate to severe VMS
3. be willing to discontinue and abstain from the following: vaginal hormonal products; transdermal or oral estrogen or estrogen/progestin combination; progestin implants; injectable estrogen; topical progesterone cream, selective estrogen receptor modulators and intrauterine devices (IUDs)
4. have no clinically significant abnormalities on pelvic exam except for vulvovaginal atrophy (VVA)
5. have a normal or clinically insignificant transvaginal ultrasound (TVU) with an endometrial thickness <4 mm at screening
6. have a normal endometrial biopsy subsequent to the TVU without clinically relevant results
7. have a normal screening Papanicolaou (Pap) smear
8. have a mammogram within 9 months prior to randomization. Subjects must have had a Breast Imaging Reporting and Data System (BI-RADS) mammography result of 1 or 2 to enroll.

Read More

Exclusion Criteria

Subjects with any of the following characteristics were not be eligible to participate in the study:

1. have a history of invasive breast cancer or ductal carcinoma in situ, melanoma or any gynecologic cancer.

2. using any of the following:

   • oral estrogen-, progestin-, androgen-, or selective estrogen receptor modulator (SERM) containing drug products within 8 weeks before screening (visit 1)
   • transdermal hormone products within 4 weeks before screening (visit 1)
   • vaginal hormone products (rings, creams, gels) within 4 weeks before screening (visit 1)
   • progestin implants/injectables, IUDs or estrogen pellets/injectables within 6 months before screening (visit 1)
   • anabolic steroids

3. have been treated with a gonadotropin-releasing hormone (GnRH) agonist within the last year

4. have been treated with anti-estrogens or aromatase inhibitors within 2 months prior to study entry

5. have been concurrently treated and will abstain from gabapentin and paroxetine or serotonin and norepinephrine reuptake inhibitors (SNRIs) for VMS or other indications for 3 months during the trial and have not taken within 4 weeks prior to screening

6. have unexplained vaginal bleeding within the 3 months prior to study entry

7. have an endometrial biopsy at baseline with a diagnosis by a gynecologic pathologist of proliferative, hyperplasia, polyp or cancer

8. have unresolved cervical cytological smear report of atypical glandular or squamous cells of undetermined significance. Cervical cytologic smear report of ASCUS, low grade squamous intraepithelial lesion or greater, or any reported dysplasia

9. have unresolved findings suspicious for malignancy on the breast examination

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Regimen 1	RAD1901	RAD1901 5 mg/day
Regimen 3	RAD1901	RAD1901 20 mg/day
Regimen 4	Placebo	Placebo
Regimen 2	RAD1901	RAD1901 10 mg/day

Primary Outcome Measures

Name	Time	Method
Change From Baseline to Week 12 in the Frequency of Moderate to Severe Hot Flashes	Baseline and 12 weeks	Change from baseline to week 12 in the average number of moderate and severe hot flashes per day, where change is calculated as week 12 minus baseline so that negative values indicate a reduction (improvement) of hot flash frequency.; Severity of hot flashes was self-assessed and reported as follows: * Mild: sensation of heat without sweating; * Moderate: sensation of heat with sweating, able to continue activity; * Severe: sensation of heat with sweating, causing cessation of activity.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline to Week 4 in the Frequency of Moderate to Severe Hot Flashes	Baseline and 4 weeks	Change from baseline to week 4 in the average number of moderate and severe hot flashes per day, where change is calculated as week 4 minus baseline so that negative values indicate a reduction (improvement) of hot flash frequency.
Change From Baseline to Week 4 and Week 12 in the Severity of Hot Flashes	Baseline, 4 weeks, and 12 weeks	Change from baseline to week 4 and week 12 in the average daily severity of hot flashes, where change is calculated as week 4 or week 12 minus baseline so that negative values indicate a reduction (improvement) of hot flash severity.; Subjects recorded the number of hot flashes per day using an electronic diary. Daily severity score for hot flashes for each subject was calculated as the sum of the number of mild hot flashes, plus 2 times the number of moderate hot flashes, plus 3 times the number of severe hot flashes, divided by the total number of mild, moderate, and severe hot flashes. That is,; Daily Severity Score = (Fmild + 2•Fmod + 3•Fsev)/(Fmild + Fmod + Fsev) where Fmild= frequency of mild hot flashes, Fmod = frequency of moderate hot flashes, Fsev = frequency of severe hot flashes.; The measure is a weighted average of the frequencies of Hot Flashes.
Change From Baseline to Week 4 and Week 12 in the Frequency of All Hot Flashes	Baseline, 4 weeks, and 12 weeks	Change from baseline to week 4 and week 12 in the average number of all hot flashes (mild, moderate, and severe) by eDiary, where change is calculated as week 4 or week 12 minus baseline so that negative values indicate a reduction (improvement) of hot flash frequency.

Trial Locations

Locations (1)

Women's Health Care Specialists P.C. - Beyer Research; 🇺🇸 Kalamazoo, Michigan, United States